Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo.
Glantschnig H, Hampton RA, Lu P, Zhao JZ, Vitelli S, Huang L, Haytko P, Cusick T, Ireland C, Jarantow SW, Ernst R, Wei N, Nantermet P, Scott KR, Fisher JE, Talamo F, Orsatti L, Reszka AA, Sandhu P, Kimmel D, Flores O, Strohl W, An Z, Wang F. Glantschnig H, et al. Among authors: cusick t. J Biol Chem. 2010 Dec 17;285(51):40135-47. doi: 10.1074/jbc.M110.166892. Epub 2010 Oct 7. J Biol Chem. 2010. PMID: 20929859 Free PMC article.
Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits.
Pennypacker BL, Duong LT, Cusick TE, Masarachia PJ, Gentile MA, Gauthier JY, Black WC, Scott BB, Samadfam R, Smith SY, Kimmel DB. Pennypacker BL, et al. Among authors: cusick te. J Bone Miner Res. 2011 Feb;26(2):252-62. doi: 10.1002/jbmr.223. J Bone Miner Res. 2011. PMID: 20734451 Free article.
Applicability of in vitro-in vivo translation of cathepsin K inhibition from animal species to human with the use of free-drug hypothesis.
Ma B, Luo B, Euler DH, Cusick TE, Wesolowski G, Glantschnig H, Duong LT, Ou Y, Carroll SS, Lubbers LS. Ma B, et al. Among authors: cusick te. Naunyn Schmiedebergs Arch Pharmacol. 2017 Apr;390(4):435-441. doi: 10.1007/s00210-017-1356-5. Epub 2017 Feb 20. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 28220210 Clinical Trial.
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology.
Schmidt A, Kimmel DB, Bai C, Scafonas A, Rutledge S, Vogel RL, McElwee-Witmer S, Chen F, Nantermet PV, Kasparcova V, Leu CT, Zhang HZ, Duggan ME, Gentile MA, Hodor P, Pennypacker B, Masarachia P, Opas EE, Adamski SA, Cusick TE, Wang J, Mitchell HJ, Kim Y, Prueksaritanont T, Perkins JJ, Meissner RS, Hartman GD, Freedman LP, Harada S, Ray WJ. Schmidt A, et al. Among authors: cusick te. J Biol Chem. 2010 May 28;285(22):17054-64. doi: 10.1074/jbc.M109.099002. Epub 2010 Mar 31. J Biol Chem. 2010. PMID: 20356837 Free PMC article.
Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A, Meissner RS, Gentile MA, Chisamore MJ, Opas EE, Scafonas A, Cusick TE, Gambone C, Pennypacker B, Hodor P, Perkins JJ, Bai C, Ferraro D, Bettoun DJ, Wilkinson HA, Alves SE, Flores O, Ray WJ. Schmidt A, et al. J Steroid Biochem Mol Biol. 2014 Sep;143:29-39. doi: 10.1016/j.jsbmb.2014.02.005. Epub 2014 Feb 22. J Steroid Biochem Mol Biol. 2014. PMID: 24565564
Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort.
Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N; Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Marenghi C, et al. Cancers (Basel). 2022 Jul 22;14(15):3558. doi: 10.3390/cancers14153558. Cancers (Basel). 2022. PMID: 35892817 Free PMC article.
44 results